Announced last summer, CMS has now instituted the WISeR program to force prior authorization into Medicare Part B using outside venders and their software.
There's a new piece about it in JAMA Internal Medicine currently. Kannarkat et al. They note,
CMS puts forth a thoughtful effort through WISeR to reduce health care waste....With WISeR, AI tools prescreen PA documentation for completeness and match against Medicare coverage rules before human review,
Well, wait a minute. Does anyone really read what CMS has done? The procedures include some with no CMS rules (for erection therapy, an old NCD says, basically, "Impotence therapy is covered when it is medically necessary.") That AI Prior Auth software may well implement ten or twenty rules and rejection triggers, but they're not CMS rules, 'cause there aren't any.
Even more alarming is the inclusion of deep brain stimulation in Parkinson's. CMS's NCD for DBS is approaching 25 years old - 2003 - and is grossly outdated. See a Chat GPT assessment of this policy mess, below. (See also an Opus 4.7 assessment).
Nobody seems to have even noticed these obvious problems in the months of large teams working on WISeR.
(Admittedly, CMS has delayed implementation of DBS in WISeR, but it took nine months to do so, and the reason doesn't seem to have anything to do with the outdated NCD.)
Chat GPT on DBS Outdated Rules
It's a mess. The CMS NCD is strikingly frozen in 2003 language. It still covers the basic durable points — idiopathic PD, levodopa responsiveness, STN/GPi targets, movement-disorders involvement, and exclusion of atypical parkinsonism — but a modern DBS center would think about DBS much differently than the NCD reads. CMS itself still lists NCD 160.24 as Version 1, effective April 1, 2003, with no ending effective date. (Centers for Medicare & Medicaid Services)
Header: For years, one of the Grand Questions in genomics has been "in house versus send out." I asked Claude Opus 4.7 to write a book chapter on how the pro's and con's currently align.
As always with "AI Guest Column," the point is not the "answer" but to show us a checkpoint on how AI currently researches data and assembles an argument.
####
Will new landmark events, like the approval of the 500-gene ILMN TSO PMA platform at FDA, shape the insource-outsource questions? I asked Claude Opus 4.7, which came back with a 20 page computer-generated book chapter on the question.
Precision oncology has advanced rapidly because genomic
testing has made cancer treatment increasingly targetable, measurable, and
data-driven. Yet the business landscape remains hard to predict: FDA approval,
strong reimbursement, and technical performance do not automatically translate
into broad adoption.
This AI-generated report (Opus 4.7) uses Illumina’s TruSight Oncology Comprehensive
assay as a test case for a larger industry question: whether distributed,
platform-based IVD kits — now reaching the scale of 500-gene comprehensive
genomic profiling — can shift oncology testing away from national reference
laboratories and back toward hospital and academic medical centers.
The analysis reviews the current market, the strategic
appeal of in-house CGP, and the barriers that may constrain adoption, including
local validation, uneven case volumes, oncologist preferences, EHR integration,
and the broader data ecosystems built by Foundation Medicine, Tempus, Caris,
and similar firms.
This report is intended to aid both investors and
policy-makers.It provides the reader
with both a market-facing review and a demonstration of how AI-generated
analysis can help frame the present state of a fast-moving field and explore
plausible paths for its evolution.
Header: Digital pathology at warp speed - Tempus acquires Paige, Roche aquires PathAI, ArteraAI gets a true FDA application (Breast cancer prognostics). What should ArteraAI do next? I asked Claude Opus 4.7 to write a guest column.
###
1. Overview
2. ArteraAI Options Map
3. What a CEO Thinks at Night
4. Using High-Low Scenario Modeling
####
1. Overview
Three AI Pathology Companies — Acquisitions, ArteraAI's Story, and Exit Landscape
Recent AI pathology acquisitions
Tempus → Paige (Aug 2025). Tempus AI acquired Paige, an AI digital pathology company, for $81.25 million, paid predominantly in Tempus common stock plus assumption of Paige's remaining Microsoft Azure commitment. Paige brought a dataset of nearly 7 million digitized pathology slides licensed from Memorial Sloan Kettering, plus a foundation model trained on more than 2.3 million whole-slide images. Tempus then launched Paige Predict in January 2026, an H&E-based biomarker prediction suite covering 123 biomarkers across 16 cancer types. Tempus AI + 2
Roche → PathAI (May 7, 2026). Roche agreed to acquire PathAI for up to $1.05 billion: $750M upfront plus up to $300M in milestone payments, with closing expected in the second half of 2026. The deal builds on a partnership established in 2021 and expanded in 2024 for AI-enabled companion diagnostic algorithms; PathAI will fold into Roche's Diagnostics division. Roche specifically wanted PathAI's Image Management System (IMS) and intends to scale it globally, pairing it with Roche's companion-diagnostics franchise. MedTech Dive + 2
The price gap is striking — roughly 13x — and reflects what each buyer was actually paying for. Tempus got a data set and a team that complement an existing oncology platform; Roche got a productized lab IT layer (AISight IMS) plus five years of co-developed companion diagnostics for its drug pipeline.
ArteraAI — origins, work, goals
(ArteraAI is a Los Altos prostate cancer company. There's a separate, unrelated Santa Barbara company called Artera.IO doing patient communications that recently raised $65M.)
Origins. ArteraAI was founded in 2021 with the goal of using AI to globally personalize medical decisions and improve outcomes for cancer patients, built on the belief that histopathology images contain signals that traditional gene-expression tests miss. CEO and co-founder Andre Esteva is well known in medical AI (lead author of the 2017 Nature dermatology-AI paper at Stanford). The company emerged from stealth in March 2023 with $90 million in funding from Coatue, Johnson & Johnson Innovation, Marc Benioff and others. A further $20M followed in February 2024, bringing total raised to roughly $110M. Amazon Web Services + 2
The work. Artera's multimodal AI (MMAI) platform combines digital biopsy images with clinical variables; the algorithm was developed using thousands of patients and tens of thousands of pathology slides, clinically validated across multiple Phase 3 randomized trials. The flagship ArteraAI Prostate Test estimates 10-year risk of distant metastasis and prostate-cancer-specific mortality and predicts hormone-therapy benefit. The SaMD version of their prostate test received FDA De Novo authorization on July 31, 2025. ArteraAI See 24 page FDA review.
Goals. Beyond prostate, the long-term goal is a pan-tumor foundation model that can assess risk and therapy benefit across any cancer sample, starting with breast cancer. Amazon Web Services
Breast cancer — SABCS 2025 abstract data
Artera presented three abstracts at the San Antonio Breast Cancer Symposium (SABCS), December 9–12, 2025. The studies leveraged data from four independent Phase III trials across Germany, Austria, and North America, validating the MMAI model across more than 7,000 patients with HR+ early breast cancer. 01net
The headline finding was from the NSABP B-20 analysis: among patients aged 50 and older, MMAI high-risk individuals experienced a 52% relative reduction in 10-year distant metastasis with chemotherapy, while MMAI low-risk patients derived no additional benefit. This is the predictive (not just prognostic) claim — the same kind of "who actually benefits from treatment" question that made Oncotype DX a multi-billion-dollar franchise in breast cancer. Morningstar
A separate development abstract used data from over 12,000 patients enrolled in six Phase III trials in the US, Germany, and Austria to build the MMAI model for predicting distant metastasis in HR+ early-stage invasive breast cancer. BioSpace
The breast test currently started a laboratory-developed test (the AMA Cat III code application for "AI prognosis of HR+/HER2- breast cancer" was pending as of Apr 30–May 2). The SABCS data package looks deliberately constructed to support both an FDA filing and the NCCN/payer evidence bar for commercial coverage.
###
###
2. Capital and Exit Options.
ArteraAI: Fundraising, Development, and Exit Options
Where Artera stands today
ArteraAI is now a meaningfully different company than it was a year ago. As of May 2026, it has:
Two FDA authorizations: ArteraAI Prostate (De Novo, July 2025) and ArteraAI Breast (510(k), May 6, 2026) — the first and only FDA-cleared digital pathology-based risk stratification tools in either indication.
European regulatory access: CE marks under EU IVDR for both the prostate biopsy assay and breast cancer assay (April 2026).
A Predetermined Change Control Plan (PCCP) allowing iterative model updates without new submissions.
NCCN guideline inclusion for prostate (since early 2024), with breast inclusion in NCCN as the logical next push.
Medicare payment [pricing] on claims for the prostate LDT, with CPT code 0376U effective since April 2023.
Commercial coverage by 73 health plans covering 70.1M lives (as of March 2026), including Anthem and Concert Genetics.
Approximately $110M raised across seed and follow-on rounds from Coatue, Johnson & Johnson Innovation, Marc Benioff, Prosperity7 Ventures and others, with the last disclosed round being a $20M extension in February 2024.
The strategic picture: Artera now has a regulated multi-cancer AI pathology platform, not just a single product. That distinction drives valuation.
Why the timing is unusually favorable
Three external developments have re-set the market for an asset like Artera:
Roche / PathAI (May 2026) — up to $1.05B ($750M upfront + $300M milestones) for a company that did not have an FDA-authorized SaMD prognostic device or NCCN-recommended status. This is the most directly relevant comp.
Tempus / Paige (August 2025) — $81.25M, mostly stock, for a data-and-team asset. Smaller, but it removed one of Artera's most visible competitors and demonstrated public-market acquirers are active.
Consolidation pressure — with two of the four most-recognized AI pathology names now inside large strategics, the remaining standalone universe is small, which makes scarcity work in Artera's favor.
Path 1: Late-stage growth round
The most straightforward near-term option. Every diagnostics-investor underwriting checkbox has now been ticked: FDA authorization (twice), CE marking, guideline inclusion, Medicare payment, commercial coverage, PCCP, and a second indication validated in Phase 3 data.
Likely size: $75–150M Series C/D range, depending on dilution tolerance.
Likely investors: existing investors plus crossover funds (T. Rowe, Fidelity, RA Capital, Perceptive) that typically come in pre-IPO for diagnostics.
Valuation argument: PathAI comp + dual FDA + reimbursement traction supports a meaningful step-up from the last round.
Use of proceeds: breast commercial launch, CPT coding and payer coverage for breast, international expansion under CE mark, and continued platform expansion to additional tumor types.
Risk: a growth round preserves optionality but doesn't lock in value at today's elevated comp environment.
Path 2: Strategic acquisition
The exit pathway most directly supported by the Roche/PathAI comp. Logical acquirers fall into three buckets:
Diagnostics incumbents include
Exact Sciences — Oncotype DX is the direct target of ArteraAI Breast. Same-day, image-only, in-lab results competing with a send-out genomic test is exactly the disruption Exact would want to own rather than fight.
Veracyte — already competes with Artera SaMD in prostate guidelines via Decipher; offensive or defensive logic both apply.
Agendia (MammaPrint) — smaller, threatened, less likely as buyer than as competitor.
Myriad Genetics, Natera — adjacent diagnostics platforms might consider for pathology AI exposure.
Pharma/diagnostics with companion-diagnostic strategy
Roche — just spent $1.05B on PathAI, but Artera's FDA-cleared prognostic SaMD with guideline inclusion is a different asset class. Possible, though probably not in the next 12 months.
Scanner and stack companies (Fujitsu, Danaher, others) — scanner and lab-IT footprint, no flagship AI pathology asset.
Tempus — already moved with Paige, but an FDA-authorized SaMD with NCCN inclusion is the kind of tuck-in they buy.
Likely deal structure: upfront + milestones, similar to PathAI. A reasonable range — using PathAI as the upper bound and adjusting for revenue scale — would be $600M–$1.2B total deal value, with substantial milestone weighting.
Path 3: IPO
Plausible but probably not the first move.
The Tempus 2024 IPO and the broader diagnostics IPO window have improved, but Artera's revenue scale is likely still below where public investors comfortably underwrite a diagnostics name.
Better positioned 18–24 months out, after breast claims revenue ramps and coverage broadens.
IPO valuation discipline tends to undervalue platform stories versus strategic buyers who can quantify cross-sell and synergy.
Path 4: Stay private and build
The "do nothing" option, which is rarely actually nothing.
Each subsequent milestone — breast CPT code, breast NCCN inclusion, breast payer coverage, third indication clearance — adds enterprise value.
The risk: pathology AI is consolidating in real time around 2–3 large platforms. A standalone with great technology can still get squeezed on distribution, hospital purchasing committees, and pharma partnership access.
Best suited if leadership has a specific milestone (e.g., $50M+ ARR or a third FDA clearance) at which they believe a markedly better exit becomes available.
What to watch over the next 6–12 months
Breast reimbursement milestones: AMA Cat III code decision for HR+/HER2-, CMS pricing, first commercial payer policies.
NCCN breast guideline inclusion: the single biggest catalyst for breast adoption and payer coverage.
A third indication: bladder, kidney, or another tumor type would convert "two-product company" to "true platform."
Strategic process signals: banker hires, named CFO with public-company experience, IPO-track audit firm engagement.
Pharma partnership announcements: companion-diagnostic deals with large oncology pharma would both generate non-dilutive revenue and signal to acquirers.
Recommended framing
The strongest argument Artera can make right now — to investors or acquirers — is that it is the only company in AI pathology with FDA authorizations in two indications, a regulated change-control mechanism, an established reimbursement footprint in one indication, and a clinically-validated pipeline behind it. That combination did not exist anywhere in the market six months ago, and the recent strategic activity has made it scarce and valuable simultaneously. Whichever path is chosen, the negotiating leverage is at a high-water mark.
###
###
3. Night Thoughts of a CEO
CEO/Chair Memo — Strategic Reflection, Mid-2026
Note: Artera has an actual CEO, but this is a FICTIONAL CEO created by Opus 4.7.
Personal working notes. Not for distribution.
What I'm thinking
We are in the best position this company has ever been in, and probably the best position we will be in for the next 18 months unless we execute nearly perfectly. That asymmetry is the thing I keep coming back to.
Six months ago we were a one-product company with a great FDA story and a real but narrow commercial footprint in prostate. Today we are — credibly, not aspirationally — a regulated multi-cancer AI pathology platform. The market just told us what that's worth: Roche paid up to $1.05B for a company that didn't have what we now have. That comp will not stay fresh forever. Strategic memory in M&A is about 12–18 months; after that, boards anchor to whatever the next deal prints, and the next deal might be smaller.
At the same time, I am acutely aware that "best position ever" is exactly the moment founders most often misread. The temptation is to believe the milestones will keep compounding linearly. They won't. Breast reimbursement is going to be a slog. The Cat III pathway is narrowing for AI [with new rules like AMA Appendix S] and possible enw AMA codes like "CMAA" - tbd.)
Payers have raised the bar. Distribution into hospital pathology labs is harder than my investor SaMD slide deck makes it look. And the consolidation around Tempus/Paige and Roche/PathAI changes the competitive dynamics in ways I don't fully understand yet — particularly around hospital purchasing committees and pharma partnership access.
So the real question isn't "what's the optimal path." It's: what decision do I need to make in the next 90 days that preserves the most optionality if I'm wrong about which path is optimal?
The core dilemma
It comes down to one trade-off, framed three ways:
Financial framing: Raise now at a high mark and dilute, or run a strategic process now and crystallize value, or push through to more milestones and risk the window closing.
Mission framing: I started this company to build a pan-tumor foundation model that personalizes cancer therapy globally. That mission survives — and arguably accelerates — inside Roche or Exact. It also survives independently with more capital. It does not survive a botched solo run that ends in a distressed sale in 2028.
Personal framing: If I sell now, I almost certainly stay on for 2–3 years inside the acquirer, then what? If I raise money and run it, I'm signing up for another 5–7 years minimum with materially higher execution risk. Neither answer is obviously wrong. Both answers have a version where I look back and wish I'd done the other.
Given my bias to an independent Artera, I should discount my own instincts here by maybe 20%.
The pivot points I'm actually weighing
1. Do we run a process now, or wait one more milestone cycle?
Arguments for now: PathAI comp is fresh, scarcity is real, we have the leverage. Arguments for waiting: breast NCCN inclusion plus first commercial payer wins plus a third FDA filing would, in theory, push us from "platform with two indications" to "the AI pathology platform" — and the multiple expansion from that re-rating could be larger than the multiple compression risk from waiting.
The honest answer is I don't know which is bigger. I think they're roughly the same magnitude, which means the tiebreaker is execution risk and team energy, not financial modeling.
2. If we raise, do we take strategic money?
A large pharma or diagnostics player taking a minority stake plus a commercial or co-development deal is the highest-information option I haven't fully explored. It lets us test partnership chemistry with a likely future acquirer without committing.
But it also signals to other potential buyers that we're "spoken for" and can suppress the open-auction dynamic later.
3. What's the right second-product priority?
We've been opportunistic — prostate, then breast because the data was there. The next one matters more strategically. Bladder is the easiest scientifically (we have the Cat III code already approved). Kidney is bigger commercially. A pan-tumor foundation model demo is more impressive to acquirers but takes longer. I don't have a clean answer and I should.
4. Commercial scale-up vs. regulatory/clinical momentum
We've been a regulatory-and-evidence machine. We have not been a commercial machine. Our hospital lab sales motion for the SaMD product is still nascent. If we're staying independent, this is the gap I lose sleep over. If we're selling, the acquirer's salesforce solves it overnight — which is itself an argument for selling, and I should be careful not to use that as a rationalization. Assuming the acquirer's sales force welcomes us and has the right incentives and skills.
5. The team question
I have people who joined to build a generational company. Some of them will be excited by an exit; some will feel sold-out. I have other people who joined for the IPO arc. Some of them will leave if we sell early.
Retention math on an acquisition has to account for who actually stays through the earnout — and a platform's value erodes fast if the AI/ML team scatters. This is not a hypothetical concern; it's the thing that determined whether Paige and PathAI were good buys for their acquirers, and we won't know the answer on those for another year.
What I'd want to know before deciding
In rough priority order:
About the market
What would ABC actually pay, and would they engage? They're the most natural defensive acquirer for the breast asset and we have no read on their appetite. A quiet, banker-led temperature check would tell us a lot without committing us.
Is Roche really done after PathAI, or are they buyers of a complementary asset within 12 months? My instinct says they're done for now, but I'd want to test it.
What did Tempus actually do with Paige post-close? If integration is going well, they're a more credible acquirer for us than the consensus thinks. If it's struggling, they're out for 2+ years.
Where is DEF strategy heading? They're the one player I can imagine making a competing bid that meaningfully changes our negotiating posture.
About our own business
What does the realistic breast revenue ramp look like over 24 months, base / bull / bear, given no CPT code yet? I have rough numbers but I want them stress-tested by someone who has actually launched a breast diagnostic before.
What's our actual hospital lab sales conversion data from the prostate SaMD early access program? Not the happy pitch deck version — the real funnel math. This tells me whether the SaMD commercial motion is working or whether we're still effectively an LDT company with FDA stickers.
What's the cash runway under each path? I think we have 18–24 months but I want to know what changes if breast launch costs more than planned.
What's the regulatory cost and timeline for a third indication, and which one maximizes platform narrative versus revenue?
About the buyers and partners
Who would do a strategic minority investment plus partnership without a path-to-acquisition lockup? This is the highest-leverage structure available to us and I don't know who's actually open to it.
What's the current pharma appetite for companion diagnostic partnerships specifically built on AI pathology? Post-PathAI, this market should be hotter, but pharma BD cycles are slow.
For each plausible acquirer: who is the actual decision-maker, what's his/her current strategic agenda, and what's their integration track record?
Generic "Roche might buy us" is not helpful to me.
"The Roche Diagnostics SVP, John Smith, who championed PathAI, is now looking for X"… I can move with that.
About the team and myself
Who on the leadership team has genuinely processed the trade-offs and can give me honest counsel versus telling me what they think I want to hear? The board can do this, but the board doesn't carry the operational weight. I need 2–3 internal voices I trust to push back.
What do I actually want? This should align but doesn't always, and I'd rather notice the gap now than discover it during a deal.
What do my co-founders think? Don't assume.
What I'd do in the next 90 days regardless of path
These are no-regret moves:
Hire a banker on a quiet retainer. Not to run a process — to give us real market intelligence and be ready if we need to move fast. Goldman, Centerview, or Jefferies for the diagnostics specialization.
Take one or two exploratory meetings. Through the banker, not direct. With ABC and one pharma. Listen, don't pitch. The information value is enormous and the commitment cost is zero.
Pressure-test the breast launch plan. Bring in 1–2 senior advisors who have personally launched competing diagnostics. Their assessment of our commercial readiness will dominate any board discussion of timing.
Lock in the AI/ML team. Refreshed equity grants, retention packages, whatever it takes. Whether we sell or scale, the model team is the asset. If they walk, every path gets worse.
Get the third-indication decision made. Not the work done — the decision. Bladder, kidney, or foundation model demo. Pick one and commit, because indecision here costs us 6 months of narrative.
Have the conversation with my co-founders and with the board chair separately. Where each of them actually is on the spectrum from "build for a decade" to "take the right offer." I should know this before any banker conversation moves past exploratory.
What I'm not going to do
I'm not going to start telling people we're "exploring strategic alternatives." The minute that phrase leaks, valuation gets harder and the team starts updating LinkedIn.
I'm not going to chase a pre-emptive offer. Pre-empts are almost always under-priced; if someone wants us badly enough to pre-empt, they'll pay more in a process.
I'm not going to over-index on the PathAI comp publicly. It's our anchor internally, but waving it around with bankers and acquirers makes us look like we've already decided to sell.
I'm not going to let the breast launch get under-resourced because we're distracted by strategic optionality. Whatever path we choose, breast commercial execution is the proof point that justifies our value. A weak launch tanks every other option and outcome.
The honest summary
The right answer is probably: raise a modest strategic round in the next 6 months with optionality built in, run a quiet market check in parallel, and make a binding decision on path by Q1 2027 when we'll have the first 6 months of breast commercial data.
That's not the bold answer. It's not the simple answer. But it's the answer that preserves the most value across the widest range of futures, which is what I'm paid to do.
I should sleep on it. And I should talk to my co-founder before I do anything that locks anything in.
###
###
4. High-Low Scenario Map
Two ArteraAI Scenarios: Mid-2026 to End-2028
Both scenarios assume the same starting point — May 2026, two FDA clearances, ~$110M raised, prostate generating real revenue, breast just cleared. Both are realistic. The point isn't to predict; it's to make the shape of each future concrete enough to plan against.
Upside Scenario: "The Platform Thesis Validates"
Mid-to-late 2026
The breast launch goes better than the board's base case. The hospital lab sales motion built for prostate transfers cleanly — same buyers, same workflow, incremental sell. Within 90 days of launch, three top-20 academic medical centers commit to integrating ArteraAI Breast alongside prostate, and one of them publishes early implementation data showing same-day reporting versus the 5–10 day send-out for Oncotype DX. That single data point becomes the entire commercial pitch.
A late-2026 growth round closes at materially higher valuation than the last mark. The round is led by a crossover fund (T. Rowe or Fidelity), with one strategic — a large pharma, not a diagnostics player — taking a minority position alongside a multi-year companion diagnostics partnership. The strategic stake is structured deliberately without right-of-first-refusal or any acquisition lockup. Total raised crosses $200M. Runway extends to 36 months.
The AMA Cat III code for breast moves through the editorial panel on the first submission, helped by the FDA clearance and the SABCS evidence package. CMS pricing follows the prostate playbook. We start billing Medicare on breast claims in Q2 2027.
Through 2027
NCCN inclusion for ArteraAI Breast in HR+/HER2- early-stage breast cancer arrives in the v2.2027 guidelines. This is the single most important commercial event in the company's history — bigger than either FDA clearance — because it forces payer coverage conversations and unlocks the academic medical center buyer who needs guideline cover to deploy.
A third indication clears FDA via 510(k) by mid-2027. The PCCP infrastructure means the submission takes 8 months instead of 18. The "platform" narrative is no longer marketing — it's three indications, two pathways, and a regulatory mechanism for continuous improvement. This is the moment Artera stops being compared to single-product diagnostics companies and starts being compared to AI platforms.
The pharma partnership generates its first milestone payment in late 2027, validating the companion diagnostic thesis. A second pharma signs a similar deal in Q4. Non-dilutive revenue becomes a real line item.
Commercial revenue hits roughly $60–80M ARR by end of 2027, growing 100%+ year-over-year, with healthy gross margins on the SaMD product and improving margins on the LDT business as volume scales.
Through 2028
Multiple things happen in parallel that compound:
A fourth indication enters FDA review.
The foundation model work matures into a demonstrable pan-tumor capability — not commercial yet, but credible enough to anchor investor conversations.
The hospital lab installed base crosses 200 sites, creating a network effect where new indications can be cross-sold into existing accounts at near-zero CAC.
A second large pharma partnership expands into a co-development arrangement.
By mid-2028, the company is in a position where three outcomes are simultaneously available:
A premium strategic acquisition at $2.5–4B. Most likely Roche (returning for a complementary asset to PathAI) or ABC (defensive, expensive). Possibly /PharmaX/ or a non-obvious pharma buyer through the partnership relationship.
An IPO in a window that opens for diagnostics names with $100M+ ARR, growth above 80%, and a platform story. Underwriters compete for the mandate.
A continued private path with another late-stage round at a $3B+ valuation, building toward a 2029–2030 outcome.
The luxury of having all three options is the actual prize. The CEO gets to choose based on what serves the mission, not what's available.
Key features of this scenario: Compounding, not breakthrough. No single miracle. Every individual step is something the company has already done at least once — clear FDA, build commercial, secure reimbursement, sign pharma. The success comes from doing all of them in parallel and on time.
Probability assessment: Plausible. Maybe 25–30%. It requires execution at roughly the 70th percentile across six independent workstreams. Each individual workstream is achievable; the conjunction is what makes it hard.
Downside Scenario: "The Slow Squeeze"
Mid-to-late 2026
The breast launch starts slower than projected. Hospital pathology lab procurement cycles are longer than the prostate experience suggested — those early prostate accounts had champions who were already digital pathology believers, and the next cohort doesn't. The first three "easy" accounts take six months to close instead of three.
The growth round happens, but it's smaller than hoped — $75–100M — and the valuation step-up is modest, around 1.5x the last mark rather than the 3x the PathAI comp suggested. The reason isn't the asset; it's the diagnostics financing environment, which softens in late 2026 when a couple of public comps miss earnings. Crossover funds pass. The round is led by existing investors with one new healthcare specialist, which is a flat-to-down signal that the strategic acquirers register.
The AMA Cat III code for breast hits a snag — not a rejection, but a request for revisions that pushes the effective date to 2028. CMS pricing follows the code, so Medicare billing on breast doesn't start when planned.
Through 2027
NCCN inclusion for breast doesn't come in the v2.2027 guidelines. The panel wants longer follow-up on the predictive (chemotherapy benefit) claim, not just the prognostic data. This is a defensible scientific position but a commercial disaster — it pushes inclusion to v2.2028 at earliest, which means most commercial payers won't write coverage policies until 2028, which means hospital lab buyers won't commit volume until coverage exists. The chicken-and-egg problem the slides described is real and we're now living inside it.
Meanwhile, two competitive dynamics get worse:
Tempus + Paige launches a breast biomarker prediction product as part of Paige Predict, leveraging their existing oncology install base and reference lab relationships. It's not as good clinically but it's bundled into a workflow customers already have. Sales cycles get harder.
Exact uses glass slide archives, which are plentiful, to develop a test that's additive with Oncotype.
Announces an AI overlay to Oncotype DX — an "Oncotype DX AI" product that adds image analysis to their existing genomic test.
It's a defensive product, scientifically weaker than ours, but it carries the brand and the payer contracts. We start hearing it in customer conversations.
A pharma partnership conversation that looked promising in early 2027 stalls. The pharma partner does a similar deal with PathAI/Roche instead, partly because Roche can offer the full integrated companion diagnostic stack and we can offer the AI piece only.
The third indication clears FDA, but later than planned — Q4 2027 instead of mid-year — and the data package was harder to assemble than expected because the right validation cohort wasn't readily available.
Revenue hits ~$30–40M ARR by end of 2027. Growth is real but is below plan, and the gross margin story is muddier than the board deck suggested because hospital lab sales have higher implementation costs than the model assumed.
Through 2028
This is the "downside" forecast, so the squeeze tightens. Three forces compound in the wrong direction:
Cash burn vs. revenue ramp. With a smaller-than-hoped 2026 round and slower revenue, runway becomes a 2028 problem. A bridge round in mid-2028 happens at flat-to-down valuation, and existing investors have to choose between supporting it and accepting dilution. The signal to outside acquirers is unmistakable.
Strategic acquirer interest cools. The Roche/PathAI integration is going well enough that Roche is uninterested in a second pathology asset. Tempus is focused on absorbing Paige. Exact's defensive AI product is in market and they no longer feel they need to buy us. The natural buyer set has effectively closed, at least for the next 18 months.
Talent risk crystallizes. Two senior AI/ML leaders leave for better-funded competitors or to start their own companies. Replacements are findable but the institutional knowledge in the foundation model work degrades. The "platform" narrative gets harder to tell honestly.
By mid-2028, the company faces a harder choice set:
A strategic acquisition at $400–700M — real money, but a fraction of the PathAI comp and well below what was achievable in 2026. The likely acquirer is a tier-2 diagnostics player or a private equity rollup, not a premium strategic. Founders and early investors do well; later investors are roughly flat.
A down round at a $600–900M post-money, with new investor protections that materially dilute the founders and reset the cap table.
A continued grind that buys time but doesn't change the trajectory — eventually leading to option 1 or 2 in 2029 on worse terms.
The IPO option is gone. It doesn't come back until 2029–2030 at earliest, and only with a meaningful inflection that's hard to engineer from this position.
Key features of this scenario: No catastrophe. No FDA rescission, no clinical scandal, no fraud. Just a series of small misses that compound. Each individual miss is recoverable; the conjunction is what creates the squeeze. The company never fails in any dramatic sense. It just becomes worth less than it should have been.
Probability assessment: Equally plausible. Maybe 25–30%. The reimbursement timeline risk is the single biggest swing factor and it's largely outside management's control.
What both scenarios share
Looking at these side by side, three observations matter more than the outcomes themselves:
1. The high-success scenario doesn't require luck — it requires reimbursement to work. The single biggest variable between the two scenarios is whether breast CPT coding, CMS pricing, NCCN inclusion, and commercial payer policy all move on schedule. That entire workstream is partially outside management's control and is the right place to over-invest attention and resources right now.
2. The downside scenario is largely about competitive dynamics, not internal execution. In the bad version, Artera doesn't fail at anything — it gets slowly squeezed by larger, better-distributed competitors. This argues for moving faster on strategic optionality, not slower, because the window where Artera looks scarce and special is open now and may not be open in 18 months.
3. The optionality value of acting in 2026 is asymmetric. A strategic conversation initiated in 2026 from a position of strength can be walked away from if the high-success path materializes. A strategic conversation initiated in 2028 from a position of weakness happens on the acquirer's terms. The cost of optionality is low; the cost of not having it is potentially enormous.
What to plan against
The right planning posture isn't to bet on the high-success scenario or to insure against the downside — it's to set up the 2026 decisions so that:
If the high-success scenario materializes, the company is positioned to choose among three good outcomes.
If the downside scenario materializes, the company has already established the relationships and information base needed to execute a strategic sale before the squeeze tightens.
The actions look similar in both cases for the next 6 months: hire the banker, take exploratory meetings, lock in the team, over-resource reimbursement work, get the third-indication decision made. The divergence in tactics happens around Q1 2027, when the first breast commercial data and the NCCN decision will tell management which world they're actually living in.
That's the practical value of running both scenarios — not to predict, but to identify the actions that look right in both, and execute those first.
###
The original output sometimes included mutiple citations widgeted together, the blog here captures the 1st one.
A big thanks to Vitali Khvatkov at Linked In for highlighting a CMS RFI on 'Prior authorization" with specific attention to the nightmare it creates for clinical laboratories. (See also a blog by Brendan Keeler). (See also a CMS announcement and Fact Sheet.)
The word Laboratory occurs 42 times, mostly in the RFI section, Section III, Part E, page 20014-16. This concerns whether labs have special added burdens when confronted with prior authorization portals and denials.
What CMS Asks For [AI Corner - Claude Opus 4.7]
####
CMS Prior Authorization RFI on Labs: What CMS Said, and What They Didn't
CMS has opened a Request for Information on prior authorization for laboratory tests (bundled with DMEPOS) inside its larger interoperability rule.
The lab RFI lives at Section III.E of CMS-0062-P, published at 91 FR 19890 on Tuesday, April 14, 2026. The framing matters: CMS is openly acknowledging — in the Federal Register, with citations — that lab prior auth in the commercial and MA worlds is generating real harm. That acknowledgment is the soft underbelly worth pressing on in comments.
Big news that Roche buys PathAI for up to $1B. I pulled together some twenty viewpoints harvested from Linked In, press releases, a Health Advances podcast, and put Chat GPT into "agentic" mode to review it all. I specifically asked for some perspective from the earlier Tempus-Paige deal.
As always with this kind of blog, the point is not exactly what stance Chat GPT takes from the material, but rather it's a case study how an AI can attempt to bring business strategy ideas together.
(See some meta-comments about how the 2000-word article was constructed by AI, as a Sidebar: Building the Article, at bottom. Also find a Sidebar tie-in with ArteraAI's breast prognostic test win at FDA.)
###
AI CORNER
###
Roche’s $1B PathAI acquisition signals that digital pathology is moving from promising software to strategic diagnostic infrastructure. Despite narrow reimbursement pathways for routine AI pathology, PathAI gives Roche a platform for workflow efficiency, biopharma services, companion diagnostics, and future computational biomarkers. Tempus’s Paige acquisition followed a different logic: enriching its multimodal oncology data engine.
Both deals suggest digital pathology’s value may come less from standalone payment than from ecosystem control.
###
Roche buying PathAI is less a bet that digital pathology will suddenly become generously reimbursed, and more a bet that AI pathology will become infrastructure for oncology diagnostics, companion diagnostics, and drug development. PathAI brings Roche an FDA-cleared image-management platform, an open AI ecosystem, enterprise deployments, biopharma trial tools, and a foundation-model strategy. Tempus buying Paige was a different but equally logical move: Tempus wanted pathology data and AI to extend its molecular, clinical, and multimodal oncology engine. In short: Roche bought a workflow/CDx platform company; Tempus bought a data/model/oncology-AI accelerator. Both may have bought the “right” digital pathology company for their own strategic problem.
Old News: Last week, CAP and some Congressionial offices announced H.R.8500, the "Timely Access to Coverage Decisions Act." Early news - Here.
New News: The legislative language is now posted!
Find the full text of the bill in "Congressional Legalese" here.
Find the full contents of the bill described in "Just Plain English" right here below.
For students seeking extra credit, the full text in Latin, here.
###
AI Corner Chat GPT
##
Timely Access to Coverage Decisions Act of 2026 —
What It Would Do in Plain English
TLDR — The bill would put a clock on the Medicare LCD process. When a MAC receives a formal LCD request or reconsideration request, it would have 60 days to say whether the request is complete. If incomplete, the MAC must identify what is missing. If complete, the MAC must act within one year. The bill also strengthens the public draft-LCD process: open meetings, remote access, expert input, posted meeting records, public comments, written responses, and a requirement that the final LCD be a logical outgrowth of the draft.
##
A new House bill, the Timely Access to Coverage Decisions Act of 2026, would put firmer timelines and procedural guardrails around how Medicare Administrative Contractors handle Local Coverage Determinations — the LCDs that decide whether Medicare will cover many services, tests, procedures, and technologies in a MAC region. The bill was introduced in April 2026, by Rep. Neal Dunn of Florida, with Reps. Nanette Barragán and Claudia Tenney as cosponsors.
In practical terms, the bill tries to solve a familiar problem: an innovator, physician group, lab, manufacturer, or other stakeholder can ask a MAC for a coverage decision, but the request may sit for a long time with no clear endpoint. This legislation would not guarantee a favorable LCD. But it would require the MAC to say whether the request is complete, identify what is missing if it is not complete, and act within a defined time period if it is complete.
See subscription coverage at Genomeweb here. (Alexandra Byrne.)
###
AI CORNER (Chat GPT)
##
UPMC Precision Medicine Report:
When “Access” Means More than Just the Test
Precision medicine has spent two decades being described as the future of care. The new UPMC/University of Pittsburgh report offers a more practical update: in many health systems, the future has arrived, but it is still stuck in the plumbing.
The issue is no longer just whether genetic tests exist, or whether they can be sent to a reference lab. The harder question is whether a health system can order the right test, manage payment, return the result, place it usefully in the EHR, interpret it, and act on it.
That is the central message of Operationalizing Precision Medicine: How U.S. Health Systems Are Implementing Genetic Testing, a 22-page report from UPMC’s Center for Connected Medicine, the University of Pittsburgh Institute for Precision Medicine, and KLAS Research. The report is based on interviews with 21 U.S. health system leaders conducted between October 2025 and February 2026. A GenomeWeb/Precision Medicine Online article by Alexandra Byrne highlighted the same theme: programs are maturing, but reimbursement remains a persistent drag.
Header: Using CLAUDE. I have been using Chat GPT exclusively for three years. Recently, friends have introduced me to areas where Claude Opus has advantages. I asked Claude Opus to review "me." I haven't altered the result - it's below.
###
Claude Opus 4.7 Researches Bruce Quinn MD
Professional Identity
Bruce Quinn is an expert on health reform, innovation, and United States health policy and payment systems — a pathologist by training who has worked on a wide range of health policy issues ranging from biopharma to genomics. His consulting practice, Bruce Quinn Associates LLC, is based in Southern California, and he is widely recognized as one of the leading independent voices on Medicare policy for diagnostics and precision medicine.
College of American Pathologists has taken the point position, for years, on improving LCDs at Medicare. For example, some of their ideas were incorporated in 21st Century Cures, which passed during the Obama-Trump transition.
New News
April 28, CAP announces creation of H.R. 8500, "Timely Access to Coverage Decisions Act" (TACDA).
I'll cut and paste the CAP News below. You can also scroll for similar text about "8500" at this CAP page here. See a media quote from CAP here.
The actual legislation for HR 8500 is not posted online yet. The lead sponsor is Rep. Neal Dunn R FL, and cosponsors are Nanette Barragan D CA and Claudia Tenney R NY.
I learned much about this when I recently asked Chat GPT to write long detailed essays on the history of each rule, 3-day and 14-day.
Since I first worked as a CMS medical director in 2004–2008, I have been familiar with Medicare date-of-service rules and their interaction with hospital billing. For inpatient admissions, Medicare generally bundles related hospital services, and all diagnostic services, furnished in the three days before admission into the inpatient DRG payment. This is the familiar three-day rule. Separately, since 2007, Medicare has applied a special laboratory 14-day rule, under which certain lab tests can be pulled back to the hospital episode based on the date of specimen collection.
I recently learned much more about these policies by asking ChatGPT to generate long, detailed essays on the history of both rules: the three-day rule and the 14-day laboratory rule.
The two rules have very different origins. The three-day rule is longstanding Medicare law, grounded directly in statute. The statute uses relatively straightforward language: diagnostic services furnished within three days before admission, and certain “related” other services furnished by the same hospital or hospital system, are treated as part of the inpatient stay and bundled into the DRG payment. It is plain English and, conceptually, simple English.
Header: Congressman Comer (KY) writes CMS, raises questions about AMA CPT structure and coding, and fraud and abuse issues.
Comer letter here. Comer press here. STAT PLUS (subsc.) here.
###
Could the complexities of US coding systems contribute to healthcare fraud? Certainly something went awry in Medicare - when the Novitas MAC got lost in the forest of CPT genetic codes and assumed some rare costly genetic codes (81408 and others) would never be needed or expected in Medicare. And therefore had no edits on them. Result: One to two billion dollars flowed out through just those unexpected codes (over s i x y e a r s, half under Trump I and half under Biden) before it was stopped.
###
RFK Jr has also raised concerns about the US coding system.
###
AI Corner
Chat GPT 5.5
###
Detailed Summary:
Comer Letter, Comer Press Release, and STAT Article on CPT Codes, AMA, and Fraud
TLDR
Takeaway Message
The Comer documents mark a notable escalation in the politics of medical coding.
CPT has long been criticized as an AMA-controlled proprietary standard, but Comer places it inside the current Washington frame of fraud, waste, abuse, and federal healthcare cost control. His letter asks CMS not only how it polices improper AMA CPT coding, but whether CMS has the authority to simplify or move away from the current CPT-based system altogether. That makes this more than a routine anti-fraud inquiry. It is potentially a challenge to one of the basic operating systems of American healthcare reimbursement.
Chat GPT summarizes the data on the recently released SERENA-6 trial and ODAC-FDA advisory board. OncLive here. Fierce Biotech here. Precision Medicine Online (Turna Ray) here.
###
Chat GPT:
SERENA-6 was a Phase III trial in HR-positive, HER2-negative advanced breast cancer testing whether therapy should be changed when an ESR1 mutation first appears in circulating tumor DNA, before conventional radiologic progression. Patients on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy were serially monitored with Guardant360 ctDNA testing. When an ESR1 mutation was detected but imaging had not yet shown progression, patients were randomized.
Blog 02 - Here - I ask Chat GPT to write about the 7 documents, based on 200,000 words in 7 transcripts (see Blog 01 including ZIP file). Prompt at bottom.
##
See Claude Opus version. See Google Notebook LM (free) version.
RFK Jr.’s Seven-Hearing Hill Marathon: April 16–22, 2026
Robert F. Kennedy Jr.’s late-April swing through Congress was not one hearing but a seven-stop stress test of his second-year leadership of HHS. The hearings ranged across House and Senate authorizers and appropriators: Ways & Means, House Appropriations, Energy & Commerce, Senate Appropriations, Senate Finance, and Senate HELP. The master file lists the seven events, their dates, committees, topics, and video links; despite the file title’s “April 14 to April 22” framing, the seven hearings documented in the source set begin on April 16 and run through April 22.
The result was a compressed portrait of Kennedy’s HHS: ambitious, disruptive, rhetorically potent, and politically combustible. His message was consistent. America is sick; the old health system is broken; HHS has been captured by profit-driven and status-quo institutions; chronic disease, nutrition, fraud, rural hospital decline, drug prices, and bureaucratic friction must be attacked at the root. He repeatedly framed the department’s agenda as a generational correction, including food policy, prior authorization, rural health, faster FDA approvals, ultra-rare disease programs, drug pricing, and fraud enforcement. In his own Ways & Means opening, he said the country was at a “generational turning point,” that children were the “sickest generation in modern history,” and that HHS was replacing policies that fueled chronic disease with policies that put Americans’ health first.
But the hearings also showed the limits of that message. Democrats repeatedly focused on vaccines, measles, CDC changes, NIH and CDC cuts, Medicaid reductions, contraception, grant terminations, and whether Kennedy’s public-health worldview had moved from skepticism into governance. Republicans, by contrast, often treated him as the rare cabinet officer who was willing to say the system was rotten and needed to be rebuilt. The result was a week in which Kennedy’s strengths and weaknesses were almost identical: he was most effective when talking broadly about incentives, chronic disease, rural care, and fraud; he was weakest when cornered on precise yes/no policy commitments, technical details, or scientific claims.
